Toxicity and response of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy for patients with locally advanced non-small cell lung cancer

A phase i trial

John H. Heinzerling, Hak Choy, Randall S. Hughes, Ramaswamy Govindan, Jeffrey D. Bradley, Lee Schwartzberg, Guangbin Peng, Joseph Treat, Taylor Tran, Coleman Obasaju

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Pemetrexed is an effective and a tolerable drug in advanced non-small cell lung cancer (NSCLC). This study sought to ascertain maximum tolerated dose (MTD) and phase II dose of carboplatin or cisplatin given with pemetrexed and concurrent chest radiation therapy (CRT) in locally advanced NSCLC. Methods: Eligible, previously untreated patients were enrolled with the initial intent of establishing the MTD of both weekly cisplatin or carboplatin combined with pemetrexed 500 mg/m2 every 3 weeks and concurrent CRT in an alternating, two arm, phase I trial. Secondary objectives included response rate and toxicity. The protocol was subsequently amended to establish the safety of planned phase II doses of cisplatin or carboplatin combined with pemetrexed 500 mg/m given every 3 weeks × 3 cycles with CRT. Results: Patients received pemetrexed combined with carboplatin area under curve = 2 (n = 9), cisplatin 30 mg/m2 (n = 9), or cisplatin 75 mg/m2 (n = 4). One dose-limiting toxicity occurred in both the carboplatin and in the cisplatin 30 mg/m2 cohorts. No dose-limiting toxicities occurred in the cisplatin 75 mg/m2 cohort. Because these are standard doses without radiation therapy in lung cancer, there was no further dose escalation. Partial response rates were 11% (carboplatin) and 46% (combined cisplatin). Stable disease rates were 33% (carboplatin) and 46% (combined cisplatin). Two patients receiving carboplatin experienced disease progression. Conclusions: The MTD of cisplatin combined with pemetrexed was not reached. Based on these and Cancer and Leukemia Group B 30407 results, pemetrexed with either carboplatin or cisplatin at full systemic doses with CRT seems to be well tolerated. A multicenter, randomized phase II trial of both regimens is underway.

Original languageEnglish (US)
Pages (from-to)1391-1396
Number of pages6
JournalJournal of Thoracic Oncology
Volume5
Issue number9
DOIs
StatePublished - Jan 1 2010

Fingerprint

Pemetrexed
Carboplatin
Non-Small Cell Lung Carcinoma
Cisplatin
Radiotherapy
Thorax
Maximum Tolerated Dose

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Toxicity and response of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy for patients with locally advanced non-small cell lung cancer : A phase i trial. / Heinzerling, John H.; Choy, Hak; Hughes, Randall S.; Govindan, Ramaswamy; Bradley, Jeffrey D.; Schwartzberg, Lee; Peng, Guangbin; Treat, Joseph; Tran, Taylor; Obasaju, Coleman.

In: Journal of Thoracic Oncology, Vol. 5, No. 9, 01.01.2010, p. 1391-1396.

Research output: Contribution to journalArticle

Heinzerling, John H. ; Choy, Hak ; Hughes, Randall S. ; Govindan, Ramaswamy ; Bradley, Jeffrey D. ; Schwartzberg, Lee ; Peng, Guangbin ; Treat, Joseph ; Tran, Taylor ; Obasaju, Coleman. / Toxicity and response of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy for patients with locally advanced non-small cell lung cancer : A phase i trial. In: Journal of Thoracic Oncology. 2010 ; Vol. 5, No. 9. pp. 1391-1396.
@article{5fadf3d91f1f40ca80c56ade475f4882,
title = "Toxicity and response of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy for patients with locally advanced non-small cell lung cancer: A phase i trial",
abstract = "Introduction: Pemetrexed is an effective and a tolerable drug in advanced non-small cell lung cancer (NSCLC). This study sought to ascertain maximum tolerated dose (MTD) and phase II dose of carboplatin or cisplatin given with pemetrexed and concurrent chest radiation therapy (CRT) in locally advanced NSCLC. Methods: Eligible, previously untreated patients were enrolled with the initial intent of establishing the MTD of both weekly cisplatin or carboplatin combined with pemetrexed 500 mg/m2 every 3 weeks and concurrent CRT in an alternating, two arm, phase I trial. Secondary objectives included response rate and toxicity. The protocol was subsequently amended to establish the safety of planned phase II doses of cisplatin or carboplatin combined with pemetrexed 500 mg/m given every 3 weeks × 3 cycles with CRT. Results: Patients received pemetrexed combined with carboplatin area under curve = 2 (n = 9), cisplatin 30 mg/m2 (n = 9), or cisplatin 75 mg/m2 (n = 4). One dose-limiting toxicity occurred in both the carboplatin and in the cisplatin 30 mg/m2 cohorts. No dose-limiting toxicities occurred in the cisplatin 75 mg/m2 cohort. Because these are standard doses without radiation therapy in lung cancer, there was no further dose escalation. Partial response rates were 11{\%} (carboplatin) and 46{\%} (combined cisplatin). Stable disease rates were 33{\%} (carboplatin) and 46{\%} (combined cisplatin). Two patients receiving carboplatin experienced disease progression. Conclusions: The MTD of cisplatin combined with pemetrexed was not reached. Based on these and Cancer and Leukemia Group B 30407 results, pemetrexed with either carboplatin or cisplatin at full systemic doses with CRT seems to be well tolerated. A multicenter, randomized phase II trial of both regimens is underway.",
author = "Heinzerling, {John H.} and Hak Choy and Hughes, {Randall S.} and Ramaswamy Govindan and Bradley, {Jeffrey D.} and Lee Schwartzberg and Guangbin Peng and Joseph Treat and Taylor Tran and Coleman Obasaju",
year = "2010",
month = "1",
day = "1",
doi = "10.1097/JTO.0b013e3181e7fe43",
language = "English (US)",
volume = "5",
pages = "1391--1396",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "9",

}

TY - JOUR

T1 - Toxicity and response of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy for patients with locally advanced non-small cell lung cancer

T2 - A phase i trial

AU - Heinzerling, John H.

AU - Choy, Hak

AU - Hughes, Randall S.

AU - Govindan, Ramaswamy

AU - Bradley, Jeffrey D.

AU - Schwartzberg, Lee

AU - Peng, Guangbin

AU - Treat, Joseph

AU - Tran, Taylor

AU - Obasaju, Coleman

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Introduction: Pemetrexed is an effective and a tolerable drug in advanced non-small cell lung cancer (NSCLC). This study sought to ascertain maximum tolerated dose (MTD) and phase II dose of carboplatin or cisplatin given with pemetrexed and concurrent chest radiation therapy (CRT) in locally advanced NSCLC. Methods: Eligible, previously untreated patients were enrolled with the initial intent of establishing the MTD of both weekly cisplatin or carboplatin combined with pemetrexed 500 mg/m2 every 3 weeks and concurrent CRT in an alternating, two arm, phase I trial. Secondary objectives included response rate and toxicity. The protocol was subsequently amended to establish the safety of planned phase II doses of cisplatin or carboplatin combined with pemetrexed 500 mg/m given every 3 weeks × 3 cycles with CRT. Results: Patients received pemetrexed combined with carboplatin area under curve = 2 (n = 9), cisplatin 30 mg/m2 (n = 9), or cisplatin 75 mg/m2 (n = 4). One dose-limiting toxicity occurred in both the carboplatin and in the cisplatin 30 mg/m2 cohorts. No dose-limiting toxicities occurred in the cisplatin 75 mg/m2 cohort. Because these are standard doses without radiation therapy in lung cancer, there was no further dose escalation. Partial response rates were 11% (carboplatin) and 46% (combined cisplatin). Stable disease rates were 33% (carboplatin) and 46% (combined cisplatin). Two patients receiving carboplatin experienced disease progression. Conclusions: The MTD of cisplatin combined with pemetrexed was not reached. Based on these and Cancer and Leukemia Group B 30407 results, pemetrexed with either carboplatin or cisplatin at full systemic doses with CRT seems to be well tolerated. A multicenter, randomized phase II trial of both regimens is underway.

AB - Introduction: Pemetrexed is an effective and a tolerable drug in advanced non-small cell lung cancer (NSCLC). This study sought to ascertain maximum tolerated dose (MTD) and phase II dose of carboplatin or cisplatin given with pemetrexed and concurrent chest radiation therapy (CRT) in locally advanced NSCLC. Methods: Eligible, previously untreated patients were enrolled with the initial intent of establishing the MTD of both weekly cisplatin or carboplatin combined with pemetrexed 500 mg/m2 every 3 weeks and concurrent CRT in an alternating, two arm, phase I trial. Secondary objectives included response rate and toxicity. The protocol was subsequently amended to establish the safety of planned phase II doses of cisplatin or carboplatin combined with pemetrexed 500 mg/m given every 3 weeks × 3 cycles with CRT. Results: Patients received pemetrexed combined with carboplatin area under curve = 2 (n = 9), cisplatin 30 mg/m2 (n = 9), or cisplatin 75 mg/m2 (n = 4). One dose-limiting toxicity occurred in both the carboplatin and in the cisplatin 30 mg/m2 cohorts. No dose-limiting toxicities occurred in the cisplatin 75 mg/m2 cohort. Because these are standard doses without radiation therapy in lung cancer, there was no further dose escalation. Partial response rates were 11% (carboplatin) and 46% (combined cisplatin). Stable disease rates were 33% (carboplatin) and 46% (combined cisplatin). Two patients receiving carboplatin experienced disease progression. Conclusions: The MTD of cisplatin combined with pemetrexed was not reached. Based on these and Cancer and Leukemia Group B 30407 results, pemetrexed with either carboplatin or cisplatin at full systemic doses with CRT seems to be well tolerated. A multicenter, randomized phase II trial of both regimens is underway.

UR - http://www.scopus.com/inward/record.url?scp=77956234834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956234834&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181e7fe43

DO - 10.1097/JTO.0b013e3181e7fe43

M3 - Article

VL - 5

SP - 1391

EP - 1396

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 9

ER -